Form 4: Apogee Therapeutics CEO Exercises Stock Options, Increases Holdings

Apogee Therapeutics CEO Michael Henderson exercised stock options on January 31, 2025, acquiring 8,500 shares of common stock.

Summary

• Michael Henderson, CEO of Apogee Therapeutics, exercised stock options on January 31, 2025.
• This transaction involved the acquisition of 8,500 shares of common stock at a price of $22.86 per share.
• Following the transaction, Mr. Henderson directly owns 1,317,987 shares of common stock.
• He also holds options to purchase 390,012 additional shares of common stock.
• The options vest over time, with a portion vesting on December 18, 2024, and the remainder vesting monthly over the next three years.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The CEO's exercise of stock options demonstrates confidence in the company's future prospects.
• The increase in the CEO's holdings aligns his interests with those of other shareholders.

Industry Context

This is a routine filing related to executive compensation and stock option exercises, common in publicly traded companies.

Comparison to Industry Standards

• Stock option exercises are a standard form of compensation for executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of the options, with a portion vesting initially and the remainder over time, is a common practice to incentivize long-term performance.
• Similar filings are regularly made by executives at comparable companies such as Regeneron, Vertex Pharmaceuticals, and BioMarin.

Stakeholder Impact

• The transaction increases the CEO's stake in the company, which can be viewed positively by shareholders.
• The vesting schedule of the options incentivizes the CEO to focus on long-term value creation.

Key Dates

Keywords

stock options, insider trading, executive compensation, beneficial ownership, Apogee Therapeutics, APGE, Michael Henderson